A randomized, evaluator blind, phase 2 study comparing safety and efficacy of omadacycline to linezolid for the treatment of complicated skin and skin-structure infections

Trial Profile

A randomized, evaluator blind, phase 2 study comparing safety and efficacy of omadacycline to linezolid for the treatment of complicated skin and skin-structure infections

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Omadacycline (Primary) ; Omadacycline (Primary) ; Linezolid; Linezolid
  • Indications Skin and soft tissue infections; Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Paratek Pharmaceuticals
  • Most Recent Events

    • 05 Jun 2017 Results of pooled post-hoc analysis presented at the ASM Microbe 2017
    • 12 Apr 2016 Results of a pooled analysis (n=377) from this and other phase III trial (see profile 32711) presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
    • 11 Apr 2016 Results of pooled analysis (n=377) from this and other phase III trial (see profile 32711) published in the Paratek Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top